Potential benefits of Big Data applications in the field of pharmaceutical research is not only in the focus of the pharmaceutical industry but also a political agenda in particular in the European Union. The panel will examine the overlap of interests of the different players by providing an overview on transparency requirements under EU regulations and its motives and potential commercial and legal benefits as well as challenges resulting from the transparency of clinical data both from a patent and data protection perspective.

Session ID: 551496